AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development of our proprietary product candidates, and where applicable, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights.
Our most advanced wholly-owned antibody programs, etokimab, ANB019, ANB030 and ANB032, are designed to modulate therapeutic targets that are genetically associated with human inflammatory disorders. We are advancing etokimab, our proprietary anti-interleukin-33 antibody, for the treatment of chronic rhinosinusitis with nasal polyps and eosinophilic asthma.
We are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our third wholly-owned program ANB030, an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases.
Our fourth wholly-owned program is an anti-BTLA modulator antibody, known as ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
Advancing our lead wholly-owned programs for the treatment of severe inflammatory disease
We are advancing etokimab, our proprietary anti-interleukin-33 antibody, for the treatment of chronic rhinosinusitis with nasal polyps and eosinophilic asthma. We are developing our anti-IL-36R antibody (ANB019) for the treatment of generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP). We are also developing ANB030, our anti-PD-1 agonist antibody program, to address to T-cell driven human inflammatory diseases, and we intend to develop ANB032, our anti-BTLA modulator antibody, in human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
Identifying emerging target biology opportunities in inflammation
We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement.
Expanding our proprietary pipeline by generating new antibody product candidates using our technology platform
Using our proprietary antibody generation platform, we are able to rapidly develop novel therapeutic antibodies against emerging targets. Our goal is to advance multiple additional wholly-owned new therapeutic antibody program to IND submission.
Retaining rights to strategic products in key commercial markets
We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development and commercialization.
Management
Hamza Suria
President and CEOHamza Suria was appointed CEO in 2011 and has since led AnaptysBio’s transformation from its early platform technology focus to the development of a robust antibody product pipeline across key therapeutic areas.
+
Eric Loumeau
Interim Chief Financial Officer and General CounselEric Loumeau joined AnaptysBio in August 2018 with more than twenty years of experience in biotech.
+
Margaret (Peggy) Marino, Ph.D.
Senior Vice President, Project ManagementMargaret Marino, Ph.D., joined AnaptysBio from Pfizer, where she was responsible for external R&D innovation and project management across a number of biologics programs within the CovX Biotech Unit.
+
Beth Mueller
Senior Vice President, Human ResourcesBeth Mueller joined AnaptysBio in October 2019 with over 20 years of experience in all aspects of human resources, including organizational development, talent acquisition, and compensation in the biotechnology industry.
+
Martin Dahl, Ph.D.
Vice President, Cell BiologyMartin Dahl, Ph.D. joined AnaptysBio in 2018 and has more than 25 years of experience in drug discovery and research.
+
Lewis Gryziewicz, Pharm.D.
Vice President, Regulatory AffairsLewis Gryziewicz, PharmD joined AnaptysBio in January 2019 with more than 30 years of experience in Regulatory Affairs and Research and Development.
+
David McKeon
Vice President, ControllerDavid McKeon joined AnaptysBio in April 2017 with more than 20 years of accounting and finance experience. Prior to joining AnaptysBio, Mr. McKeon served as Chief Financial Officer for Mad Catz Interactive, Inc., a designer and manufacturer of video game peripherals.
+
Stephen Parmley, Ph.D.
Vice President, Molecular Biology & Protein SciencesStephen Parmley joined AnaptysBio in November of 2015 with more than 30 years of experience in protein engineering, immunology and project leadership.
+
John Wisler, PH.D., DABT
Vice President, Toxicology and PharmacologyJohn Wisler joined AnaptysBio in June 2020 with more than 30 years of industry experience leading over 40 nonclinical drug development projects.
+Board Of Directors
James N. Topper, M.D., Ph.D.
Chairman of AnaptysBio Managing General Partner at Frazier HealthcareJamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 11 years as a General Partner, Dr. Topper has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.
+Hollings Renton
Former President and CEO of Onyx PharmaceuticalsHollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008.
+John Schmid
Former CFO of Auspex PharmaceuticalsJohn Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015. Prior to Auspex, he co-founded Trius Therapeutics, Inc., where he served as Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. in September 2013.
+Dennis Fenton, Ph.D.
Former Executive Vice President, AmgenDr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President.
+J. Anthony Ware, M.D.
Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and CompanyDr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.
+Laura J. Hamill
Former Executive Vice President, Worldwide Commercial Operations, for Gilead SciencesLaura J. Hamill joined our Board of Directors in September 2019. Ms. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions.
+Hamza Suria
President and CEO, AnaptysBio, Inc.Hamza Suria was appointed CEO in 2011 and has since led AnaptysBio’s transformation from its early platform technology focus to the development of a robust antibody product pipeline across key therapeutic areas.
+Research and Development Committee
Michael Gallatin, Ph.D.
Former Vice President and Scientific Director of ICOS CorporationMichael Gallatin, Ph.D., is a former Vice President and Scientific Director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of Tadalafil (Cialis®).
+Christopher Hunter, Ph.D.
Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary MedicineChristopher Hunter, Ph.D. is the Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine. Dr. Hunter’s research has focused on the host’s immune response to infections and the innate events that lead to the development of long term protective immunity mediated […]
+John G. Monroe, Ph.D.
Emeritus Professor, University of Pennsylvania School of MedicineJohn G. Monroe, Ph.D., is an Emeritus Professor at the Perelman School of Medicine at the University of Pennsylvania. He is a former Senior Director at Genentech where he led the Immunology Discovery Department that is responsible for new target discovery and pre-clinical validation.
+Dennis Fenton, Ph.D.
Former Executive Vice President, AmgenDr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President.
+James N. Topper, M.D., Ph.D.
Chairman of AnaptysBio Managing General Partner at Frazier HealthcareJamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 11 years as a General Partner, Dr. Topper has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.
+J. Anthony Ware, M.D.
Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and CompanyDr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.
+Contact
AnaptysBio, Inc.
10421 Pacific Center Court
Suite 200
San Diego, CA 92121
Phone: (858) 362-6295
Fax: (858) 362-6296
info@anaptysbio.com
General Information
Job Opportunities
Please see our Job Openings page.